Literature DB >> 2453509

Antidiabetic sulfonylureas control action potential properties in heart cells via high affinity receptors that are linked to ATP-dependent K+ channels.

M Fosset1, J R De Weille, R D Green, H Schmid-Antomarchi, M Lazdunski.   

Abstract

Both avian and mammalian heart cells have high affinity receptors for antidiabetic sulfonylureas. The biochemical identification of these receptors has been carried out with [3H]glibenclamide. The Kd values for the most potent sulfonylureas, such as glibenclamide itself, are in the nanomolar range. Comparative studies of structure-function relationships indicate high similarities of binding properties between the sulfonylurea receptors in cardiac cells and insulinoma cells, respectively. The duration of the action potential of guinea pig cardiac cells was drastically reduced by decreasing intracellular ATP concentrations by perfusion or by blockade of oxidative phosphorylation. Glibenclamide was found to restore normal or nearly normal action potential properties in [ATP]in-depleted cardiac cells. Single channel recording using the patch-clamp technique has shown that this effect is associated with high affinity blockade of ATP-sensitive K+ channels by sulfonylureas.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2453509

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  74 in total

1.  Impaired beta-adrenoceptor mediated venodilation in patients with diabetes mellitus.

Authors:  K Harada; M Ohmori; Y Kitoh; K Sugimoto; A Fujimura
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

2.  Anoxia induces time-independent K+ current through KATP channels in isolated heart cells of the guinea-pig.

Authors:  K Benndorf; G Bollmann; M Friedrich; H Hirche
Journal:  J Physiol       Date:  1992-08       Impact factor: 5.182

3.  ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells.

Authors:  Edward C Y Wang; Jey-Myung Lee; Wily G Ruiz; Elena M Balestreire; Maximilian von Bodungen; Stacey Barrick; Debra A Cockayne; Lori A Birder; Gerard Apodaca
Journal:  J Clin Invest       Date:  2005-08-18       Impact factor: 14.808

Review 4.  ATP-dependent potassium channels of muscle cells: their properties, regulation, and possible functions.

Authors:  N W Davis; N B Standen; P R Stanfield
Journal:  J Bioenerg Biomembr       Date:  1991-08       Impact factor: 2.945

5.  Blockade of ATP-sensitive potassium channels by 5-hydroxydecanoate suppresses monophasic action potential shortening during regional myocardial ischemia.

Authors:  K Moritani; T Miyazaki; S Miyoshi; M Asanagi; L S Zhao; H Mitamura; S Ogawa
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

6.  ATP-sensitive K-channels in HIT T15 beta-cells studied by patch-clamp methods, 86Rb efflux and glibenclamide binding.

Authors:  I Niki; R P Kelly; S J Ashcroft; F M Ashcroft
Journal:  Pflugers Arch       Date:  1989-10       Impact factor: 3.657

7.  Distinct modes of blockade in cardiac ATP-sensitive K+ channels suggest multiple targets for inhibitory drug molecules.

Authors:  I Benz; M Kohlhardt
Journal:  J Membr Biol       Date:  1994-12       Impact factor: 1.843

8.  Partial contribution of the ATP-sensitive K+ current to the effects of mild metabolic depression in rabbit myocardium.

Authors:  F de Lorenzi; S Cai; O F Schanne; E Ruiz Petrich
Journal:  Mol Cell Biochem       Date:  1994-03-30       Impact factor: 3.396

9.  The sulphonylurea receptor SUR1 regulates ATP-sensitive mouse Kir6.2 K+ channels linked to the green fluorescent protein in human embryonic kidney cells (HEK 293).

Authors:  S A John; J R Monck; J N Weiss; B Ribalet
Journal:  J Physiol       Date:  1998-07-15       Impact factor: 5.182

10.  Effects of beraprost on the transmembrane potentials of guinea-pig ventricular muscles during normoxia and hypoxia-reoxygenation.

Authors:  Y Ueno; K Shigenobu; S Nishio
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.